A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention
Article 2015 en
Authors
AC
Andrew C. Chen
AM
Andrew Martin
BC
Bonita Choy
Abstract
1 min read
Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients. (Funded by the National Health and Medical Research Council; ONTRAC Australian New Zealand Clinical Trials Registry number, ACTRN12612000625875.).
Nicholas Allen, Andrew Martin, Victoria A. Snaidr, Renee Eggins, Alvin H Chong, Pablo Fernández‐Peñas, Douglas L. Gin, Shireen Sidhu, Vanessa L. Paddon, Leith Banney, Adrian Lim, Edward Upjohn, Helmut Schaider, Aparna D. Ganhewa, Jennifer Nguyen, Catriona McKenzie, Saurabh Prakash, Catriona McLean, Alistair Lochhead, Jan Ibbetson, Andrew Dettrick, Anthony Landgren, Katherine J. Allnutt, Clare Allison, Rachael Davenport, Blake P. Mumford, Brittany Wong, Brendan Stagg, Alexander Tedman, Hannah Gribbin, Harrison A. Edwards, Nicholas De Rosa, T. D. Stewart, Brent J. Doolan, Yonatan Kok, Kate Simpson, Zhi M. Low, Tom Kovitwanichkanont, Richard A Scolyer, Haryana M. Dhillon, Janette L. Vardy, Steven J. Chadban, David G. Bowen, Andrew C. Chen, Diona L. Damian
Andrew Martin, Andrew Chen, Bonita Choy, Pablo Fernández‐Peñas, Gary M. Halliday, Robyn A. Dalziell, Catriona McKenzie, Richard A Scolyer, Haryana M. Dhillon, Janette L. Vardy, Gaya St George, Nira Chinniah, Diona L. Damian
Vanessa L. Bock, J. Guy Lyons, Xiaoshui Huang, Alexandra M. Jones, L.A. McDonald, Richard A Scolyer, F.J. Moloney, Ross StC. Barnetson, Glenda M. Halliday
Discussion(0)
No comments yet. Be the first to comment.